The Mouse Anti-B. Pertussis FHA IgG ELISA Kit detects and quantifies B. pertussis FHA-specific IgG in mouse serum or plasma of vaccinated or immunized animals. This immunoassay is suitable for:
o Determining immune status relative to non-immune controls;
o Assessing efficacy of vaccines, including dosage, adjuvantcy, route of immunization and timing;
o Qualifying and/or standardizing vaccine batches and protocols.
The kit contains no active toxin or inactivated bacteria. The antigen used is highly purified pertussis toxoid (non-toxic). For in vitro research use only (RUO), not for therapeutic or diagnostic use.
The microtiter well plate and all other reagents, if unopened, are stable at 2-8°C until the expiration date printed on the box label.
The FHA coating level, HRP conjugate concentration and Low NSB Sample Diluent are optimized to differentiate anti-FHA IgG from background (non-antibody) signal with mouse serum samples diluted 1:100.
Pertussis, also known as Whooping Cough, is a highly contagious disease caused by Bordetella pertussis bacteria. Vaccines for pertussis, available in combination with vaccines for tetanus, diphtheria, H. influenza b, hepatitis & polio, use acellular components, primarily the inactivated pertussis toxin. The toxin, a protein exotoxin, produced only by B. pertussis, is central to pertussis pathogenesis; vaccination with the toxoid elicits high levels of protection from the disease. Also included are two other highly immunogenic pertussis proteins: pertactin, an outer membrane protein that promotes adhesion to host cells, and filamentous hemagglutinin (FHA).